http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109265565-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109265565-B |
| titleOfInvention | anti-CD 79b chimeric antigen receptor carrying molecular switch, immune cell modified by same and application of immune cell |
| abstract | The invention relates to an anti-CD 79b chimeric antigen receptor carrying a molecular switch, a modified immune cell thereof and application thereof, wherein the anti-CD 79b chimeric antigen receptor carrying the molecular switch comprises an anti-CD 79b chimeric antigen receptor and a molecular switch connected to the anti-CD 79b chimeric antigen receptor, and the anti-CD 79b chimeric antigen receptor comprises a signal peptide (Leader), an antigen binding region domain capable of being combined with a tumor surface antigen CD79b, a hinge region (hinge), a transmembrane domain, a costimulatory signal conduction region and a CD3 zeta signal conduction domain. The anti-CD 79b chimeric antigen receptor carrying the molecular switch and the immune cell have high structural stability, can be used for treating malignant tumors expressing CD79b surface antigens, can prevent the injury to patients caused by off-target effect or cytokine release syndrome, and have high safety. |
| priorityDate | 2018-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 602.